Leap Therapeutics (LPTX) Projected to Post Quarterly Earnings on Wednesday

Leap Therapeutics (NASDAQ:LPTX) is expected to announce its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 9:30 AM ET.

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). On average, analysts expect Leap Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Leap Therapeutics Stock Down 0.4%

Leap Therapeutics stock opened at $0.42 on Wednesday. The stock has a 50-day simple moving average of $0.43 and a 200 day simple moving average of $0.38. Leap Therapeutics has a 12-month low of $0.22 and a 12-month high of $3.92. The stock has a market capitalization of $17.30 million, a price-to-earnings ratio of -0.26 and a beta of -0.06.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LPTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Leap Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut Leap Therapeutics to a “strong sell” rating in a report on Saturday, October 18th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $3.38.

Institutional Trading of Leap Therapeutics

An institutional investor recently raised its position in Leap Therapeutics stock. Acadian Asset Management LLC raised its stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 470.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,280,531 shares of the company’s stock after buying an additional 1,056,047 shares during the quarter. Acadian Asset Management LLC owned about 3.09% of Leap Therapeutics worth $389,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.